TABLE 2.
Crohn disease patients: Acute flare
| Patient | Age, years | CDAI |
GLP-2 levels, pmol/L
|
Sugar absorption, %
|
Ratio | |||
|---|---|---|---|---|---|---|---|---|
| Fasting | Postprandial | 3-OMG | Lactulose | Mannitol | ||||
| 1 | 13 | 190 | 13 | 19 | 49.9 | 1.4 | 15.2 | 0.092 |
| 2 | 15 | 180 | 11 | 24 | 51.8 | 0.7 | 18.1 | 0.039 |
| 3 | 15 | 210 | 14 | 20 | 40.7 | 2.1 | 23.6 | 0.092 |
| 4 | 11 | 220 | 25 | 25 | 39.2 | 1.3 | 25.1 | 0.039 |
| 5 | 17 | 180 | 14 | 22 | 41.3 | 0.9 | 18.4 | 0.041 |
| 6 | 14 | 190 | 11 | 12 | 37.6 | 0.6 | 17.7 | 0.034 |
| 7 | 18 | 200 | 45 | 47 | 43.5 | 1.4 | 26.2 | 0.056 |
| Mean ± SD | 15.3±1.3 | 196±15† | 19.0±12.4 | 24.1±10.9*† | 43.4±5.4*† | 1.20±0.51 | 20.6±4.3*† | 0.056±025*† |
Glucagon-like peptide 2 (GLP-2) levels determined by radioimmunoassay using a specific antibody for intact GLP-2 (amino acid residues 1 to 33) (20). Sugar probe absorption is reported as the proportion of orally administered probe recovered in urine after an overnight collection, quantified using high-performance liquid chromatography (23,34).
*
P<0.05 versus controls;
†
P<0.01 versus patients in remission (by ANOVA). 3-OMG 3-O-methyl glucose; CDAI Crohn disease activity index